Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19.Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19.Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.[GRAPHICS].

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis / C. Baigent, S. Windecker, D. Andreini, E. Arbelo, E. Barbato, A.L. Bartorelli, A. Baumbach, E.R. Behr, S. Berti, H. Bueno, D. Capodanno, R. Cappato, A. Chieffo, J. Collet, T. Cuisset, G. De Simone, V. Delgado, P. Dendale, D. Dudek, T. Edvardsen, A. Elvan, J.R. Gonzalez-Juanatey, M. Gori, D. Grobbee, T.J. Guzik, S. Halvorsen, M. Haude, H. Heidbuchel, G. Hindricks, B. Ibanez, N. Karam, H. Katus, F.A. Klok, S.V. Konstantinides, U. Landmesser, C. Leclercq, S. Leonardi, M. Lettino, G. Marenzi, J. Mauri, M. Metra, N. Morici, C. Mueller, A.S. Petronio, M.M. Polovina, T. Potpara, F. Praz, B. Prendergast, E. Prescott, S. Price, P. Pruszczyk, O. Rodriguez-Leor, M. Roffi, R. Romaguera, S. Rosenkranz, A. Sarkozy, M. Scherrenberg, P. Seferovic, M. Senni, F.R. Spera, G. Stefanini, H. Thiele, D. Tomasoni, L. Torracca, R.M. Touyz, A.A. Wilde, B. Williams. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 43:11(2022), pp. 1033-1058. [10.1093/eurheartj/ehab696]

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

D. Andreini;A.L. Bartorelli;M. Gori;N. Morici;F.R. Spera;
2022

Abstract

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19.Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19.Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.[GRAPHICS].
ACE2; Arrhythmias; Biomarkers; COVID-19; Cardiogenic shock; Myocardial injury; Myocarditis; Non-invasive imaging; Humans; Pandemics; Prospective Studies; COVID-19; Cardiology; Cardiovascular Diseases
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Article (author)
File in questo prodotto:
File Dimensione Formato  
ehab696.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 6.45 MB
Formato Adobe PDF
6.45 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/936510
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 31
social impact